Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
Chung-Shien Lee,1,2 Matthew Milone,3 Nagashree Seetharamu2 1Department of Clinical Health Professions, St. John’s University, Queens, NY, USA; 2Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Lake Success, NY, USA; 3Pharmacy Department, Long Island Jewish Medical Cent...
Main Authors: | Lee CS, Milone M, Seetharamu N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-08-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/osimertinib-in-egfr-mutated-lung-cancer-a-review-of-the-existing-and-e-peer-reviewed-fulltext-article-OTT |
Similar Items
-
Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01) -
Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01) -
Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
by: Ruiting Lin, et al.
Published: (2021-09-01) -
Osimertinib making a breakthrough in lung cancer targeted therapy
by: Zhang H
Published: (2016-09-01) -
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
by: de Langen, A.J, et al.
Published: (2022)